(Reuters) - U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for ...
Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...
New studies to be presented at the American Heart Association meeting focus on disparities in Wegovy prescriptions and ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...
Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics;PIONEER study expands ...
Maryland’s policymakers should expand Medicaid coverage to include weight loss medications, writes Michelle Rogers.